Press release
Investigation announced for Investors in Allarity Therapeutics, Inc. (NASDAQ: ALLR) over possible Violations of Securities Laws
An investigation for investors in Allarity Therapeutics, Inc. (NASDAQ: ALLR) shares over potential securities laws violations.
Investors who purchased shares of Allarity Therapeutics, Inc. (NASDAQ: ALLR), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm focuses on whether a series of statements by Allarity Therapeutics, Inc. regarding its business, its prospects and its operations were materially false and misleading at the time they were made.
Boston, MA based Allarity Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing oncology therapeutics using drug-specific companion diagnostics generated by its drug response predictor technology.
On July 22, 2024, before market hours Allarity Therapeutics, Inc. filed a current report on Form 8-K with the Securities and Exchange Commission ("SEC"), in which the Company disclosed that: "Allarity Therapeutics, Inc. (the 'Company') received a 'Wells Notice' from the Staff of the U.S. Securities and Exchange Commission (the 'SEC') relating to the Company's previously disclosed SEC investigation."
Allarity Therapeutics, Inc. also revealed that "[t]he Wells Notice relates to the Company's disclosures regarding meetings with the United States Food and Drug Administration (the 'FDA') regarding the Company's NDA [New Drug Application] for Dovitinib or Dovitinib-DRP," and that "Allarity also understands that three of its former officers received Wells Notices from the SEC relating to the same conduct." Further, "[t]he Wells Notice informed the Company that the SEC Staff has made a preliminary determination to recommend that the SEC file an enforcement action against the Company that would allege certain violations of the federal securities laws."
Shares of Allarity Therapeutics, Inc. (NASDAQ: ALLR) declined to $0.138 per share on August 07, 2024.
Those who purchased shares of Allarity Therapeutics, Inc. (NASDAQ: ALLR) have certain options and should contact the Shareholders Foundation.
Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com
About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities lawsuits, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Investigation announced for Investors in Allarity Therapeutics, Inc. (NASDAQ: ALLR) over possible Violations of Securities Laws here
News-ID: 3647215 • Views: …
More Releases from Shareholders Foundation, Inc.
Lawsuit Notice: Investors who lost money with Alexandria Real Estate Equities, I …
An investor, who purchased shares of Alexandria Real Estate Equities, Inc. (NYSE: ARE), filed a lawsuit over alleged violations of Federal Securities Laws by Alexandria Real Estate Equities, Inc. in connection with certain allegedly false and misleading statements.
Investors who purchased shares of Alexandria Real Estate Equities, Inc. (NYSE: ARE) have certain options and for certain investors are short and strict deadlines running. Deadline: January 26, 2026. NYSE: ARE investors should…
Lawsuit filed for Investors who lost money withs shares of StubHub Holdings, Inc …
An investor, who purchased shares of StubHub Holdings, Inc. (NYSE: STUB), filed a lawsuit over alleged violations of Federal Securities Laws by StubHub Holdings, Inc. in connection with certain allegedly false and misleading statements made connection with StubHub's September 17, 2025 initial public offering (the "IPO").
Investors who purchased shares of StubHub Holdings, Inc. (NYSE: STUB) have certain options and for certain investors are short and strict deadlines running. Deadline:…
Jayud Global Logistics Limited (NASDAQ: JYD) Investor Alert: Lawsuit alleges Mis …
An investor, who purchased shares of Jayud Global Logistics Limited (NASDAQ: JYD), filed a lawsuit in the U.S. over alleged violations of Federal Securities Laws by Jayud Global Logistics Limited in connection with certain allegedly false and misleading statements made between April 21, 2023 and April 30, 2025.
Investors who purchased shares of Jayud Global Logistics Limited (NASDAQ: JYD) have certain options and for certain investors are short and strict deadlines…
Lawsuit Alert: Investors who lost money with shares of Skye Bioscience, Inc. (NA …
An investor, who purchased shares of Skye Bioscience, Inc. (NASDAQ: SKYE), filed a lawsuit over alleged violations of Federal Securities Laws by Skye Bioscience, Inc. in connection with certain allegedly false and misleading statements.
Investors who purchased shares of Skye Bioscience, Inc. (NASDAQ: SKYE) have certain options and for certain investors are short and strict deadlines running. Deadline: January 16, 2026. NASDAQ: SKYE investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com…
More Releases for Allarity
DelveInsight's Ovarian Cancer Pipeline Report Highlights 180+ Industry Trailblaz …
The Ovarian Cancer treatment landscape is evolving, driven by cutting-edge research and innovative therapies from top pharmaceutical players, offering renewed hope for patients.
DelveInsight's "Ovarian Cancer Pipeline Insight, 2025" comprehensively analyzes the current clinical landscape and growth prospects in the Ovarian Cancer market. The report covers disease insights, treatment guidelines, and a detailed pipeline assessment from preclinical to marketed stages. It includes drug mechanisms, clinical studies, regulatory progress, and key developments…
Investigation announced for Long-Term Investors in shares of Allarity Therapeuti …
An investigation on behalf of current long-term investors in shares of Allarity Therapeutics, Inc. (NASDAQ: ALLR) concerning potential breaches of fiduciary duties by certain directors and officers of Allarity Therapeutics, Inc. was announced.
Investors who are current long term investors in Allarity Therapeutics, Inc. (NASDAQ: ALLR) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm for…
Lawsuit filed for Investors who lost money with shares of Allarity Therapeutics, …
An investor, who purchased shares of Allarity Therapeutics, Inc. (NASDAQ: ALLR), filed a lawsuit over alleged violations of Federal Securities Laws by Allarity Therapeutics, Inc.
Investors who purchased shares of Allarity Therapeutics, Inc. (NASDAQ: ALLR) have certain options and for certain investors are short and strict deadlines running. Deadline: November 12, 2024. NASDAQ: ALLR investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
Boston, MA based Allarity…
Lawsuit filed for Investors who lost money with shares of Allarity Therapeutics, …
An investor, who purchased shares of Allarity Therapeutics, Inc. (NASDAQ: ALLR), filed a lawsuit over alleged violations of Federal Securities Laws by Allarity Therapeutics, Inc. in connection with certain allegedly false and misleading statements.
Investors who purchased shares of Allarity Therapeutics, Inc. (NASDAQ: ALLR) have certain options and for certain investors are short and strict deadlines running. Deadline: November 12, 2024. NASDAQ: ALLR investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com…
Ovarian Cancer Pipeline 2024 | Allarity Therapeutics, OSE Immunotherapeutic, Cri …
DelveInsight's, "Ovarian Cancer Pipeline Insight 2024" report provides comprehensive insights about 180+ companies and 200+ pipeline drugs in the Ovarian Cancer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Request a sample and discover the recent advances in Ovarian…
Ovarian Cancer Drugs Market Size 2032 | Genmab, AstraZeneca, On Target Laborator …
DelveInsight's "Ovarian Cancer Market Insights, Epidemiology, and Market Forecast - 2032" report delivers an in-depth understanding of the Ovarian Cancer, historical and forecasted epidemiology as well as the Ovarian Cancer market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Key Takeaways from Ovarian Cancer Market Report
• The rate of new cases of ovarian cancer was 10.6 per 100,000 women per year. The death rate…
